600 related articles for article (PubMed ID: 26635921)
1. Vascular endothelial dysfunction and pharmacological treatment.
Su JB
World J Cardiol; 2015 Nov; 7(11):719-41. PubMed ID: 26635921
[TBL] [Abstract][Full Text] [Related]
2. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
3. Protection of endothelial function: targets for nutritional and pharmacological interventions.
Sudano I; Spieker LE; Hermann F; Flammer A; Corti R; Noll G; Lüscher TF
J Cardiovasc Pharmacol; 2006; 47 Suppl 2():S136-50; discussion S172-6. PubMed ID: 16794451
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blockers, endothelial dysfunction, and combination therapy.
Schulman IH; Zachariah M; Raij L
Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):40-5. PubMed ID: 16640172
[TBL] [Abstract][Full Text] [Related]
5. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease.
Lyons D
Int J Cardiol; 1997 Dec; 62 Suppl 2():S101-9. PubMed ID: 9488201
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
Landmesser U; Drexler H
J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological approach to restore endothelial dysfunction.
Dobarro D; Gómez-Rubín MC; Sanchez-Recalde A; Moreno R; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):212-22. PubMed ID: 19689260
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
Higashi Y; Chayama K; Yoshizumi M
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation.
Simonsen U; Rodriguez-Rodriguez R; Dalsgaard T; Buus NH; Stankevicius E
Pharmacol Rep; 2009; 61(1):105-15. PubMed ID: 19307698
[TBL] [Abstract][Full Text] [Related]
10. The endothelium in coronary artery disease.
Ruschitzka FT; Noll G; Lüscher TF
Cardiology; 1997; 88 Suppl 3():3-19. PubMed ID: 9397288
[TBL] [Abstract][Full Text] [Related]
11. Endothelial function and oxidative stress in cardiovascular diseases.
Higashi Y; Noma K; Yoshizumi M; Kihara Y
Circ J; 2009 Mar; 73(3):411-8. PubMed ID: 19194043
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the renin angiotensin system: implications for the endothelium.
Savoia C; Schiffrin EL
Curr Diab Rep; 2006 Aug; 6(4):274-8. PubMed ID: 16879778
[TBL] [Abstract][Full Text] [Related]
13. [Role of nitric oxide and other endothelium-derived factors].
Stankevicius E; Kevelaitis E; Vainorius E; Simonsen U
Medicina (Kaunas); 2003; 39(4):333-41. PubMed ID: 12738901
[TBL] [Abstract][Full Text] [Related]
14. The endothelium in health and in cardiovascular disease.
Garćia-Palmieri MR
P R Health Sci J; 1997 Jun; 16(2):136-41. PubMed ID: 9285990
[TBL] [Abstract][Full Text] [Related]
15. Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs.
Su JB
Curr Pharm Des; 2017; 23(40):6215-6222. PubMed ID: 28641545
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Wassmann S; Laufs U; Bäumer AT; Müller K; Ahlbory K; Linz W; Itter G; Rösen R; Böhm M; Nickenig G
Hypertension; 2001 Jun; 37(6):1450-7. PubMed ID: 11408394
[TBL] [Abstract][Full Text] [Related]
18. Optimal vascular protection: a case for combination antihypertensive therapy.
Vogel RA
Prev Cardiol; 2006; 9(1):35-41. PubMed ID: 16407701
[TBL] [Abstract][Full Text] [Related]
19. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator.
Vanhoutte PM; Zhao Y; Xu A; Leung SW
Circ Res; 2016 Jul; 119(2):375-96. PubMed ID: 27390338
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition.
Bermúdez V; Bermúdez F; Acosta G; Acosta A; Añez J; Andara C; Leal E; Cano C; Manuel V; Hernández R; Israili Z
Am J Ther; 2008; 15(4):326-33. PubMed ID: 18645335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
